Last Updated: 07 Sep 2024
Executive Summary
Bristol-Myers Squibb Company (BMY) is a global pharmaceutical company with a strong portfolio of products in oncology, immunology, and cardiovascular disease. The company has a market capitalization of $98.7 billion and is currently trading at $48.7. The stock has a forward P/E ratio of 7.11 and a dividend yield of 0.0482%.
Company Overview
Bristol-Myers Squibb was founded in 1887 and is headquartered in New York City. The company has operations in over 50 countries and employs approximately 32,000 people. Bristol-Myers Squibb's product portfolio includes blockbuster drugs such as Opdivo, Yervoy, and Eliquis.
Fundamental Analysis
Bristol-Myers Squibb's financial performance has been mixed in recent years. The company's revenue has grown steadily, but its earnings have been volatile. In 2023, the company reported revenue of $46.5 billion and net income of $1.9 billion. The company's gross profit margin is 78.2%, and its operating margin is 21.3%.
Bristol-Myers Squibb's balance sheet is strong. The company has $19 billion in cash and equivalents and $20 billion in debt. The company's debt-to-equity ratio is 0.53.
Technical Analysis
The technical analysis of Bristol-Myers Squibb's stock indicates that the stock is in a downtrend. The stock has been trading below its 50-day and 200-day moving averages for the past several months. The stock's relative strength index (RSI) is currently at 35.4, which indicates that the stock is oversold.
Short Term Outlook
The short-term outlook for Bristol-Myers Squibb's stock is negative. The stock is in a downtrend and is trading below its moving averages. The RSI is also indicating that the stock is oversold.
Long Term Outlook
The long-term outlook for Bristol-Myers Squibb's stock is positive. The company has a strong product portfolio and a solid financial foundation. The company is also expected to benefit from the growing demand for pharmaceuticals.
Analyst Recommendations
The majority of analysts have a hold rating on Bristol-Myers Squibb's stock. The average analyst target price is $46.55.
